Agios Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGIO research report →
Companywww.agios.com
Agios Pharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.
- CEO
- Brian Goff
- IPO
- 2013
- Employees
- 486
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $1.69B
- P/E
- -3.96
- P/S
- 25.66
- P/B
- 1.51
- EV/EBITDA
- -3.44
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 82.07%
- Op Margin
- -719.97%
- Net Margin
- -639.84%
- ROE
- -34.11%
- ROIC
- -41.43%
Growth & Income
- Revenue
- $54.03M · 48.03%
- Net Income
- $-412,781,000 · -161.27%
- EPS
- $-7.12 · -160.03%
- Op Income
- $-472,132,000
- FCF YoY
- 3.64%
Performance & Tape
- 52W High
- $46.00
- 52W Low
- $22.24
- 50D MA
- $29.44
- 200D MA
- $32.57
- Beta
- 0.58
- Avg Volume
- 1.06M
Get TickerSpark's AI analysis on AGIO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 2, 26 | Burns James William | other | 8,500 |
| Apr 2, 26 | Burns James William | sell | 3,280 |
| Apr 2, 26 | Burns James William | other | 8,500 |
| Apr 2, 26 | Gheuens Sarah | other | 8,500 |
| Apr 2, 26 | Gheuens Sarah | sell | 2,940 |
| Apr 2, 26 | Gheuens Sarah | other | 8,500 |
| Apr 2, 26 | Jones Cecilia | other | 8,500 |
| Apr 2, 26 | Jones Cecilia | sell | 3,141 |
| Apr 2, 26 | Jones Cecilia | other | 8,500 |
| Apr 2, 26 | Milanova Tsveta | other | 8,500 |
Our AGIO Coverage
We haven't published any research on AGIO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AGIO Report →